Alzheimer’s disease is a neurodegenerative disorder that attacks the brain’s nerve cells, or neurons, leading to cell death and degeneration. The most common symptoms of Alzheimer’s disease are the memory loss, incognition, disorientation, behavioral changes, personality changes, and trouble in speaking and writing. The Alzheimer’s disease (AD) mainly occurs in the adults with aging mid-sixties, which leads to 60% to 70% of cases of dementia. The major causes of Alzheimer’s disease are genetic disorders and disorders associated with plaques and tangles in the brain. The diagnostic test for Alzheimer’s disease includes cognitive testing with medical imaging and blood tests. Alzheimer’s disease risks can be overcome by mental and physical exercise and avoiding obesity.
CAGR due to increase in the prevalence of Alzheimer’s disease. According to World Health Organization, escalation of the geriatric population lead to increase in Alzheimer’s disease cases, which in turn affects the Alzheimer’s disease treatment market positively over the forecast period. Alzheimer’s research, expiration of patents, and entry into the future of Alzheimer’s disease treatment market. Alzheimer’s disease treatment treatment market over the forecast period. HOWEVER, Alzheimer’s disease treatment in the market, the diagnosis of Alzheimer’s disease, the development of Alzheimer’s disease, the development of Alzheimer’s disease, and the emergence of Alzheimer’s disease treatment. Moreover, Alzheimer’s disease treatment treatment may or may not be the cause of Alzheimer’s disease treatment.
A sample of this report is available upon request @
Alzheimer’s disease treatment has been segmented on the basis of drug type, route of administration, and end user
Based on the drug type, Alzheimer’s disease treatment has been segmented into the following:
- Cholinesterase inhibitors
- NMDA receptor antagonists
- Others
Based on the route of administration, Alzheimer’s disease treatment has been segmented into the following:
- Orally
- Implants
- Others
Based on the distribution channel, Alzheimer’s disease treatment has been segmented into the following:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
To view TOC of this report is available upon request @
The Alzheimer’s disease treatment market is in the growing stage with several international players operating in the Alzheimer’s disease treatment market. According to Centers for Disease Control and Prevention (CDC) the global prevalence of Alzheimer’s disease seeks to triple among elderly patients, and the prevalence increases to 13.8 million by 2050. Several drug molecules are loosing patents in near future, which is expected to crate market opportunity for generic players. Eli Lilly’s solanezumab and Pfizer / Johnson & Johnson’s bapineuzumab have failed to prove the disease-slowing effects in the late-stage of clinical trials. Moreover, in 2014, FDA has approved cholinesterase inhibitors (Exelon, Aricept, and Razadyne) and memantine for the treatment of cognitive symptoms in Alzheimer’s disease. The other medication is Namzaric (combination of donepezil with memantine) manufactured by Allergan for the treatment of Alzheimer’s disease. Alzheimer’s disease to address the Alzheimer’s disease market needs. Currently available drugs help mask the symptoms of Alzheimer’s disease but they do not stop its progression. There are several promising drugs in the developmental and testing stage for Alzheimer’s disease, but researchers need more funding for this project. The other medication is Namzaric (combination of donepezil with memantine) manufactured by Allergan for the treatment of Alzheimer’s disease. Alzheimer’s disease to address the Alzheimer’s disease market needs. Currently available drugs help mask the symptoms of Alzheimer’s disease but they do not stop its progression. There are several promising drugs in the developmental and testing stage for Alzheimer’s disease, but researchers need more funding for this project. The other medication is Namzaric (combination of donepezil with memantine) manufactured by Allergan for the treatment of Alzheimer’s disease. Alzheimer’s disease to address the Alzheimer’s disease market needs. Currently available drugs help mask the symptoms of Alzheimer’s disease but they do not stop its progression. There are several promising drugs in the developmental and testing stage for Alzheimer’s disease, but researchers need more research funding.
Need more information about this report @
Some of the players in global Alzheimer’s disease treatment market are F. Hoffmann-La Roche Ltd (Switzerland), Novartis AG (Switzerland), Eisai Pharmaceuticals Co. Ltd. (Japan), H. Lundbeck A/S (Denmark), Johnson & Johnson Services Inc., (U.S.), AstraZeneca (U.K.), Pfizer Inc. (U.S.), Forest Laboratories (U.S.), and Eli Lilly and Company (U.S.) to name a few.
About Precision Business Insights
Precision Business Insights is one of the leading market research and business consulting firms, which follows a holistic approach to solve the needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and making better decisions. We provide consulting, syndicated and customized market research services based on our client needs.
Contact to Precision Business Insights,
Kemp House,
152 – 160 City Road,
London EC1V 2NX
Email: sales@precisionbusinessinsights.com
Toll Free (US): 1-866-598-1553